Results 31 to 40 of about 8,031,878 (242)

Early Impact of Childhood Opportunity on Neurocognitive Outcomes in Sickle Cell Disease

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neurocognitive impairment is a well‐recognized complication of sickle cell disease (SCD) that begins early in childhood and persists across development. While cerebrovascular injury contributes substantially to risk, neurocognitive deficits are also observed in children without overt or silent cerebral infarctions, suggesting ...
Julia E. LaMotte, Hannah Koch, Olivia A. Coughlin, Jillian R. Bouck, Allie Carter, Seethal A. Jacob   +5 more
wiley   +1 more source

Fuldt nummer

Dansk Universitetspaedagogisk Tidsskrift, 2017
Nummeret indeholder følgende artikler: Hvordan begrunder undervisere forelæsninger? Et interviewstudie med undervisere fra to fagmiljøer Anna Bager-Elsborg Læring i Modvind: Hvordan forbedrer man de studerendes præstation i fag, som de typisk ...
DUT 22
doaj  

Psychosocial Functioning After Pediatric Bone Sarcoma: Generic and Survivor‐Specific Outcomes in Adolescent and Young Adult Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric bone sarcoma patients and survivors may experience psychosocial challenges related to childhood cancer after their intensive, body‐altering treatment. This cross‐sectional study aimed to evaluate generic and survivor‐specific psychosocial outcomes in a national cohort of pediatric bone sarcoma patients and survivors, and ...
Hinke van der Hoek, Heleen Maurice‐Stam, Laura R. Beek, Jennifer van Dijk, Marjolein E. M. Langemeijer, Relinde W. Slooff‐Lentink, Alied M. van der Aa‐van Delden, Anne Westerweel, Marloes van Gorp, Hendrik W. B. Schreuder, Lianne M. Haveman, W. Peter Bekkering, Leonie G. Tigelaar, Johannes H. M. Merks, Martha A. Grootenhuis   +14 more
wiley   +1 more source

Atmena žurnalo autoriams

Aktualu Rytoj, 2022
Redakcinės kolegijos parengti nurodymai ...
Aktualu rytoj, 2022, t. 2, Nr. 22
doaj  

Identification of Three Distinct Eggplant Subgroups within the Solanum aethiopicum Gilo Group from Côte d’Ivoire by Morpho-Agronomic Characterization

Agriculture, 2014
The Solanum aethiopicum Gilo group, described as homogeneous, shows a high diversity, at least at the morphological level. In Côte d’Ivoire, farmers distinguish three subgroups, named “N’Drowa”, “Klogbo” and “Gnangnan”, within this group.
Auguste Kouassi, Eric Béli-Sika, Tah Yves-Nathan Tian-Bi, Oulo Alla-N'Nan, Abou B. Kouassi, Jean-Claude N'Zi, Assanvo S.-P. N'Guetta, Bakary Tio-Touré   +7 more
doaj   +1 more source

Ironic Medications: A Narrative‐Based Psycho‐Educational Intervention to Explore Patient–Provider Communication in Adolescents With Haematological Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adolescents with haematological malignancies face significant emotional and relational challenges, often accompanied by difficulties in communicating their needs within the healthcare context. To address these issues, a narrative‐based psycho‐educational intervention based on the creation and prescription of Ironic Medications was ...
Marta Stoppa, Elena Pagani Bagliacca, Selena Russo, Giulia Rampoldi, Maria Grazia Strepparava, Adriana Cristina Balduzzi, Andrea Biondi, Marco Spinelli   +7 more
wiley   +1 more source

Incidence and Severity of Carboplatin‐Associated Hearing Loss in Children With Cancer Assessed by the SIOP Boston 2012 Ototoxicity Criteria

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Platinum‐based chemotherapy is known to cause severe and debilitating hearing loss, but unlike cisplatin, the true incidence of carboplatin‐induced hearing loss remains unclear. We evaluated functional hearing outcomes in children receiving carboplatin to determine the incidence and severity of ototoxicity. Procedure We identified a
Aniket Chawla, Sean Carter, Andrew Wood, Sandra Staffieri, Andrew Dodgshun, David D. Eisenstat, Michael Sullivan   +6 more
wiley   +1 more source

Prevention

Deutsche Zeitschrift für Sportmedizin, 2023
Pitsiladis Y, 5, Hamilton B, Geistlinger M, Bermon S, 8, Bigard X, 5, 9, Migliorini S, Wolfarth B, 11, Di Luigi L, 12, Ionescu A, 13, Schneider C, 14, Bachl N, 15, 16, Miller M, Shroff M, Singleton P, Constantinou D, 18, Swart J, 19, Beltrami G, 21, Arroyo F, 22, Badtieva V, 23, 24, Kaux J-F, 25, Rozenštoka S, 5, 26, 27, Dienstbach-Wech L, Casajus JA, 29, Zelekova I, 29, Steinacker JM, 30, Ülkar B, 31, Papadopoulou T, 5, 32, Webborn N, Casasco M, 5, 34, Fossati C, 4, 35, Barrett J, Bilzon JLJ, 37, Dohi M, 38, Li G, 39, Ak E, 40, Pedrinelli A, 41, Pigozzi F, 4, 35   +73 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source